- Amended Statement of Ownership (SC 13G/A)
September 27 2010 - 4:06PM
Edgar (US Regulatory)
|
UNITED
STATES
|
|
|
SECURITIES
AND EXCHANGE COMMISSION
|
|
|
Washington,
D.C. 20549
|
|
|
|
|
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. 1)*
Trubion
Pharmaceuticals, Inc.
(Name of Issuer)
Common
Stock, par value $0.001 per share
(Title of Class of
Securities)
(CUSIP Number)
(Date of Event
Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
o
|
Rule 13d-1(b)
|
x
|
Rule 13d-1(c)
|
o
|
Rule 13d-1(d)
|
*The remainder of this cover page shall be filled out for a reporting
persons initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that
section of the Act, but shall be subject to all other provisions of the Act
(however, see the Notes).
CUSIP No. 89778N102
|
13G
|
|
|
|
1
|
Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (Entities Only)
Abbott Biotherapeutics Corp. (f/k/a Facet Biotech
Corporation)
|
|
|
2
|
Check the Appropriate Box
if a Member of a Group (See Instructions)
|
|
|
(a)
|
o
|
|
|
(b)
|
o
|
|
|
3
|
SEC Use Only
|
|
|
4
|
Citizenship or Place of
Organization
Delaware
|
|
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5
|
Sole Voting Power
0
|
|
6
|
Shared Voting Power
0
|
|
7
|
Sole Dispositive Power
0
|
|
8
|
Shared Dispositive Power
0
|
|
|
9
|
Aggregate Amount
Beneficially Owned by Each Reporting Person
0
|
|
|
10
|
Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions)
o
|
|
|
11
|
Percent of Class
Represented by Amount in Row (9)
0.0%
|
|
|
12
|
Type of Reporting Person
(See Instructions)
CO
|
|
|
|
|
|
|
|
|
2
Item 1.
|
|
(a)
|
Name of Issuer:
Trubion Pharmaceuticals, Inc.
|
|
(b)
|
Address of Issuers
Principal Executive Offices:
2401 Fourth Avenue, Suite 1050
Seattle, WA 98121
|
|
Item 2.
|
|
(a)
|
Name of Person Filing:
Abbott Biotherapeutics Corp. (f/k/a Facet Biotech Corporation)
|
|
(b)
|
Address of Principal
Business Office, or if none, Residence:
1500 Seaport Boulevard, Redwood City, CA 94063
|
|
(c)
|
Citizenship:
Delaware
|
|
(d)
|
Title of Class of
Securities:
Common Stock, par value $0.001 per share
|
|
(e)
|
CUSIP Number:
89778N102
|
|
Item 3.
|
If this statement is filed pursuant
to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
|
(a)
|
o
|
Broker or dealer
registered under Section 15 of the Act (15 U.S.C. 78o);
|
|
(b)
|
o
|
Bank as defined in Section
3(a)(6) of the Act (15 U.S.C. 78c);
|
|
(c)
|
o
|
Insurance company as
defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
|
|
(d)
|
o
|
Investment company
registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C.
80a-8);
|
|
(e)
|
o
|
An investment adviser in
accordance with Rule 13d-1(b)(1)(ii)(E);
|
|
(f)
|
o
|
An employee benefit plan
or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
|
|
(g)
|
o
|
A parent holding company
or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
|
|
(h)
|
o
|
A savings association as
defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.
1813);
|
|
(i)
|
o
|
A church plan that is
excluded from the definition of an investment company under Section 3(c)(14)
of the Investment Company Act of 1940 (15 U.S.C. 80a-3); or
|
|
(j)
|
o
|
Group, in accordance with
Rule 13d-1(b)(1)(ii)(J).
|
3
Item 4.
|
Ownership.
|
|
(a)
|
Amount beneficially
owned:
0 shares
|
|
(b)
|
Percent of class:
0.0%
|
|
(c)
|
Number of shares as to
which the reporting person has:
|
|
|
(i)
|
Sole power to direct the
vote:
0
|
|
|
(ii)
|
Shared power to vote or
direct the vote:
0
|
|
|
(iii)
|
Sole power to dispose or
direct the disposition of:
0
|
|
|
(iv)
|
Shared power to dispose or
direct the disposition of:
0
|
|
|
|
|
Facet Biotech
Corporation, a Delaware Corporation (the Company), was acquired by Abbott
Laboratories, an Illinois corporation (Abbott), pursuant to a transaction
that was completed on April 21, 2010 (the Acquisition). Following the
Acquisition, the Companys name was changed to Abbott Biotherapeutics Corp. In connection with the integration of the
Company into Abbott following the Acquisition, on September 27, 2010, the
Company transferred beneficial ownership of all 2,243,649 shares of common
stock, par value $0.001 of Trubion Pharmaceuticals, Inc. previously acquired
by the Company as reported on Schedule 13G filed by the Company on September
9, 2009, to Abbott.
|
|
Item 5.
|
Ownership of Five Percent or Less
of a Class.
|
If this statement is
being filed to report the fact that as of the date hereof the reporting
person has ceased to be the beneficial owner of more than five percent of the
class of securities, check the following:
x
|
|
Item 6.
|
Ownership of More than Five Percent
on Behalf of Another Person.
|
|
Not applicable.
|
|
|
Item 7.
|
Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent
Holding Company.
|
|
Not applicable.
|
|
Item 8.
|
Identification and Classification
of Members of the Group.
|
|
Not applicable.
|
|
Item 9.
|
Notice of Dissolution of Group.
|
|
Not applicable.
|
|
|
Item 10.
|
Certifications.
|
|
Not applicable.
|
4
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement
is true, complete and correct.
Date:
September 27, 2010
|
ABBOTT BIOTHERAPEUTICS CORP.
|
|
|
|
By:
|
/s/
John A. Berry
|
|
Name: John A. Berry
|
|
Its: Assistant Secretary
|
5
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Apr 2024 to May 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From May 2023 to May 2024